Sarah J. Lord
About
Sarah J. Lord is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Sarah J. Lord has authored 171 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 38 papers in Surgery. Recurrent topics in Sarah J. Lord's work include Lung Cancer Treatments and Mutations (23 papers), Health Systems, Economic Evaluations, Quality of Life (20 papers) and Cancer Genomics and Diagnostics (19 papers). Sarah J. Lord is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Health Systems, Economic Evaluations, Quality of Life (20 papers) and Cancer Genomics and Diagnostics (19 papers). Sarah J. Lord collaborates with scholars based in Australia, United States and United Kingdom. Sarah J. Lord's co-authors include Chee Khoon Lee, Val Gebski, Les Irwig, James Chih‐Hsin Yang, Nehmat Houssami, Matthew Links, Johnathan Man, Tony Mok, Stefano Ciatto and Petra Macaskill and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and The Journal of Immunology.
In The Last Decade
Sarah J. Lord
165 papers receiving 6.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sarah J. Lord Australia | 36 | 2.5k | 1.9k | 1.2k | 1.1k | 965 | 171 | 6.4k | ||
| Sudeep Gupta India | 34 | 2.5k 1.0× | 1.2k 0.6× | 1.1k 0.9× | 608 0.5× | 1.3k 1.4× | 377 | 6.2k | ||
| Joe Ensor United States | 41 | 2.4k 0.9× | 1.5k 0.8× | 1.3k 1.0× | 490 0.4× | 1.2k 1.3× | 166 | 6.3k | ||
| Eva Steliarova‐Foucher France | 26 | 3.8k 1.5× | 2.2k 1.2× | 1.2k 1.0× | 635 0.6× | 1.4k 1.4× | 54 | 9.3k | ||
| Maria Teresa Sandri Italy | 41 | 4.1k 1.6× | 1.3k 0.7× | 1.3k 1.0× | 1.3k 1.1× | 889 0.9× | 151 | 9.5k | ||
| Erik H.F.M. van der Heijden Netherlands | 32 | 1.7k 0.7× | 3.1k 1.6× | 922 0.8× | 1.1k 0.9× | 858 0.9× | 121 | 6.1k | ||
| Martin Krapcho United States | 10 | 3.6k 1.4× | 2.0k 1.1× | 1.0k 0.8× | 462 0.4× | 1.3k 1.3× | 14 | 8.2k | ||
| Matt Hayat United States | 5 | 3.3k 1.3× | 1.9k 1.0× | 956 0.8× | 462 0.4× | 1.2k 1.3× | 6 | 7.9k | ||
| Ryan Woods Canada | 33 | 2.9k 1.1× | 4.0k 2.1× | 1.7k 1.4× | 527 0.5× | 672 0.7× | 116 | 8.9k | ||
| Marie‐Josèphe Horner United States | 11 | 3.6k 1.4× | 1.9k 1.0× | 993 0.8× | 445 0.4× | 1.3k 1.3× | 26 | 8.2k | ||
| R. Swindell United Kingdom | 49 | 2.3k 0.9× | 1.8k 0.9× | 997 0.8× | 700 0.6× | 1.5k 1.6× | 166 | 6.1k |
Countries citing papers authored by Sarah J. Lord
Since
Specialization
Citations
This map shows the geographic impact of Sarah J. Lord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah J. Lord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah J. Lord more than expected).
Fields of papers citing papers by Sarah J. Lord
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sarah J. Lord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah J. Lord. The network helps show where Sarah J. Lord may publish in the future.
Co-authorship network of co-authors of Sarah J. Lord
This figure shows the co-authorship network connecting the top 25 collaborators of Sarah J. Lord. A scholar is included among the top collaborators of Sarah J. Lord based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah J. Lord. Sarah J. Lord is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Woodford, Rachel, Peey‐Sei Kok, Sarah J. Lord, et al.. (2024). Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials. JCO Precision Oncology. 8(8). e2300296–e2300296.
2.
Lord, Sarah J., Belinda E. Kiely, Dianne L. O’Connell, et al.. (2023). Characteristics and post-metastasis survival of recurrent metastatic breast cancer over time – An Australian population-based record linkage study, 2001–2016. European Journal of Cancer. 197. 113468–113468.
3.
Lord, Sarah J., Benjamin Daniels, Dianne L. O’Connell, et al.. (2023). Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016. Cancer Epidemiology Biomarkers & Prevention. 33(2). 314–324.
4.
Lord, Sarah J., Benjamin Daniels, Belinda E. Kiely, et al.. (2022). Long term risk of distant metastasis in women with non‐metastatic breast cancer and survival after metastasis detection: a population‐based linked health records study. The Medical Journal of Australia. 217(8). 402–409.
5.
Woodford, Rachel, Sarah J. Lord, Ian C. Marschner, et al.. (2022). PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology. 18(14). 1793–1799.
6.
Woodford, Rachel, Peey‐Sei Kok, Sarah J. Lord, et al.. (2022). The validity of progression‐free survival 2 as a surrogate trial end point for overall survival. Cancer. 128(7). 1449–1457.
7.
Gebski, Val, et al.. (2022). Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer. 170. 169–178.
8.
Friedländer, Michael, Sarah J. Lord, Rebecca Asher, et al.. (2021). Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer. 154. 190–200.
9.
Daniels, Benjamin, Belinda E. Kiely, Mónica Tang, et al.. (2021). Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. The Breast. 58. 106–112.
10.
Chiam, Karen, Suzanne Hughes, James G. Kench, et al.. (2021). Use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance for low-risk prostate cancer: a scoping review on the benefits and harm of mpMRI in different biopsy scenarios. Prostate Cancer and Prostatic Diseases. 24(3). 662–673.
11.
White, Sam, Lin Zhu, Jenny Doust, et al.. (2021). Simulations found within-subject measurement variation in glycaemic measures may cause overdiagnosis of prediabetes and diabetes. Journal of Clinical Epidemiology. 145. 20–28.
12.
Hudson, Harold, et al.. (2019). The association between ethnicity and pre‐eclampsia in Australia: A multicentre retrospective cohort study. Australian and New Zealand Journal of Obstetrics and Gynaecology. 60(3). 396–404.
13.
Askie, Lisa, et al.. (2018). Assessment of NICE and USPSTF guidelines for identifying women at high risk of pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: An individual participant data meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 229. 159–166.
14.
Daniels, Benjamin, Sarah J. Lord, Belinda E. Kiely, et al.. (2017). Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. BMJ Open. 7(1). e014439–e014439.
15.
Fisher, Oliver M., Sarah J. Lord, Dan Falkenback, et al.. (2016). The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. Gut. 66(3). 399–410.
16.
Ray, J. G., et al.. (2016). The performance of risk prediction models for pre‐eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review. BJOG An International Journal of Obstetrics & Gynaecology. 123(9). 1441–1452.
17.
Lim, Wai H., Jonathan C. Craig, Jeremy R. Chapman, et al.. (2015). The Relative Benefits and Costs of Solid Phase Bead Technology to Detect Preformed Donor Specific Antihuman Leukocyte Antigen Antibodies in Determining Suitability for Kidney Transplantation. Transplantation. 99(5). 957–964.
18.
Lee, Chee Khoon, David Goldstein, Emma Gibbs, et al.. (2015). Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer. 51(7). 852–860.
19.
Fisher, Oliver M., Angelique Levert‐Mignon, Sarah J. Lord, et al.. (2014). High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma. Annals of Surgical Oncology. 22(7). 2431–2438.
20.
Fox, Peter, Harold Hudson, Chris Brown, et al.. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer. 109(1). 147–153.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sudeep Gupta Breakdown of academic impact, for papers by Joe Ensor Breakdown of academic impact, for papers by Eva Steliarova‐Foucher Breakdown of academic impact, for papers by Maria Teresa Sandri Breakdown of academic impact, for papers by Erik H.F.M. van der Heijden Breakdown of academic impact, for papers by Martin Krapcho Breakdown of academic impact, for papers by Matt Hayat Breakdown of academic impact, for papers by Ryan Woods Breakdown of academic impact, for papers by Marie‐Josèphe Horner Breakdown of academic impact, for papers by R. Swindell